TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Short Term Comparison of Two Different Techniques of Uterine Cesarean Incision Closure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Singleton pregnancy~* Term (\> 37 weeks) pregnancy~* Cervical dilatation \< 4 cm~* Kerr incision~* Age \> 18 years old~Exclusion Criteria:~* Being in active phase of labor~* Emergency situations (fetal distress, cord prolapse, placental abruption,severe pre-eclampsia, eclampsia, placenta previa, vasa previa )~* Having a history of uterine surgery (myomectomy, hysterotomy)other than C/S~* Extension of Kerr incision~* Multiple pregnancy~* Maternal diabetes mellitus~* Maternal connective tissue disease~* Uterine malformation~* Uterine fibroids on Kerr incision line~* Chorioamnionitis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Purse string closure technique (Type: ACTIVE_COMPARATOR): Eighty four patients were allocated to the study group. Due to expanded Kerr incisions 4 patients in study group did not receive their allocated intervention. In addition, 29 patients in the study group were lost to follow up and did not come to the sixth week check up. Statistical analysis is based on data from the remaining 51 study group.
- Continuously locked closure technique (Type: ACTIVE_COMPARATOR): Eighty four patients were allocated to the control group. Due to expanded Kerr incisions 3 patients in control group did not receive their allocated intervention. In addition, 16 patients in the control group were lost to follow up and did not come to the sixth week check up. Statistical analysis is based on data from the remaining 65 study group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: African-American Heart Failure Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
* African American male or female 18 years or older.~* NYHA Class 3 \& 4.~* Have either a resting LVEF less than or equal to 35% (by any method) or a resting LVIDD greater than 2.9 cm/m2 BSA (or greater than 6.5 cm) with LVEF less than 45% (by echocardiogram).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and women 18-79 years of age with high cholesterol and high triglycerides.~Exclusion Criteria:~* Individuals who do not meet specific cholesterol or triglyceride levels as required by the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged ≥18 years and ≤ 60 years.~* Absolute neutrophil count (ANC) of \>1000/mm3 for African black population and ≥ 1600/mm3 for all other races.~* For Cohort 2: HIV-negative~* For Cohorts 1 and 3: HIV-1 positive; CD4 count of at least 300/mm3; HIV-1 RNA copies (viral load) \>10 000 copies/mL serum; and current physical health stable and not requiring antiretroviral treatment~* For Cohorts 1 and 3: Chest x-ray showing absence of active infectious diseases (such as tuberculosis, viral or atypical bacteria or parasitic infection).~Exclusion Criteria:~* Presence of any severe concomitant disease.~* History of or current, recurrent or recent (4 weeks) febrile disease.~* History of opportunistic infections, neoplasm or AIDS-defining conditions.~* Inability to discontinue any medication from screening onwards, or for at least 2 weeks before the first admission; in particular any antiviral or therapy with immunosuppressive activity.~* Significant liver impairment: aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≥ 2.5 times the upper normal limit.~* Significant kidney impairment: serum creatinine ≥ two times the upper normal limit.~* Any concomitant disorder or resultant therapy likely to have interfered with subject compliance or with study procedures.~* Known hypersensitivity to any of the test materials or related compounds.~* Positive test for Hepatitis B and/or C antibodies.~* A history of multiple and/or severe allergies to drugs or foods or a history of anaphylactic reactions.~* History of seizures or epilepsy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Subjects in this arm were asymptomatic HIV-infected individuals who received a dose of 33 mg/kg deferiprone three times a day for a total daily dosage of 99 mg/kg
- Cohort 2 (Type: EXPERIMENTAL): Subjects in this arm were healthy volunteers who received a dose of 50 mg/kg deferiprone three times a day for a total daily dosage of 150 mg/kg
- Cohort 3 (Type: EXPERIMENTAL): Subjects in this arm were asymptomatic HIV-infected individuals who received a dose of 50 mg/kg deferiprone three times a day for a total daily dosage of 150 mg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Established diagnosis of Waldenström macroglobulinemia (the 2nd Workshop on Waldenstrom's macroglobulinemia) or Lymphoplasmacytic lymphoma or Splenic Marginal Zone Lymphoma, needing a treatment~* Life expectancy \> 6 months~* Creatinine \< 200 µmol/l~* SGPT and SGOT \< 2x ULN~* A negative direct Coombs test~* Written informed consent~Exclusion Criteria:~* Past chemotherapy/radiotherapy/immunotherapy prior to the study for Waldenström macroglobulinemia~* Previous malignancy less than 5 years ago except carcinoma in situ of the cervix and non-melanoma skin cancer~* Positive HIV serology~* Active Hepatitis B or C~* Lactation/pregnancy~* Impossible good compliance with the study protocol~* Active infection not controlled~* Psychological condition hampering understanding of the study~* Transformation into large B cell lymphoma~* Peripheral neuropathy \> grade II

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Chlorambucil 8mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months
- 2 (Type: ACTIVE_COMPARATOR): Fludarabine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influenza Vaccination in Immunocompromized Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult outpatients treated at the Inselspital Bern for:~* HIV infection~* rheumatologic diseases and receiving immunosuppressive drugs~* kidney transplant recipients~* undergoing hemodialysis or continuous ambulatory peritoneal dialysis~* written informed consent~Exclusion Criteria:~* Allergy to egg proteins~* Former adverse reactions to prior vaccination~* Febrile conditions at the time of study inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Virosomal influenza vaccine (Type: EXPERIMENTAL): None
- Subunit influenza vaccine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Nicotine Patches Together With E-cigarettes (With and Without Nicotine) for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Smoke and want to quit in the next three months~* Reside in New Zealand~* At least 18 years of age~* Able to provide verbal consent~* Have access to telephone (mobile and/or landline)~* Are prepared to use a nicotine patch or a nicotine patch and e-cigarette together.~* Only one person per household is eligible.~Exclusion Criteria:~* Pregnant women~* Women who are breastfeeding~* Current users of NRT products~* People currently enrolled in another smoking cessation programme or other cessation study~* People who have used an e-cigarette for more than one week in the last year for smoking cessation~* Current users of non-nicotine based cessation therapies (e.g. buproprion, clonidine, nortriptyline or varenicline).~* People who have had a heart attack, stroke or severe angina within the previous two weeks.~* People who self-report a history of severe allergies and/or poorly controlled asthma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Patch (Type: ACTIVE_COMPARATOR): 21mg nicotine patch daily for 14 weeks (including a 2 week prequit period) plus behavioural support for six weeks post-quit
- Patch and nicotine-free e-cigarette (Type: ACTIVE_COMPARATOR): 21mg nicotine patch (daily) and nicotine-free e-cigarette (ad libitum) for 14 weeks (including a 2 week prequit period), plus behavioural support for six weeks post-quit
- Patch and nicotine e-cigarette (Type: ACTIVE_COMPARATOR): 21mg nicotine patch (daily) and nicotine e-cigarette (ad libitum) for 14 weeks (including a 2 week prequit period), plus behavioural support for six weeks post-quit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female subjects aged greater than and equal to (\>=) 12 years at the screening visit.~* Chronic atopic dermatitis (according to American Academy of Dermatology Consensus Criteria) that has been present for at least 2 years before the screening visit.~* Eczema Area and Severity Index (EASI) score \>=16 at the screening and baseline visits.~* Investigator Global Assessment (IGA) score \>= 3 (scale of 0 to 4) at the screening and baseline visits.~* AD involvement \>= 10 percent (%) of body surface area (BSA) at screening and baseline visits.~* Peak Pruritus Numerical Rating Scale (PPNRS) score of at least 4.0 at the screening and baseline visits.~* Documented recent history of inadequate response to topical medications (topical corticosteroids \[TCS\] with or without Topical calcineurin inhibitors \[TCI\]).~* Female subjects of childbearing potential (that is, fertile, following menarche and until becoming postmenopausal unless permanently sterile) must agree either to be strictly abstinent throughout the study and for 12 weeks after the last study drug injection or to use an adequate and approved method of contraception throughout the study and for 12 weeks after the last study drug injection.~Key Exclusion Criteria:~* Body weight (\<) 30 kilograms (kg)~* Exacerbation of asthma requiring hospitalization in the preceding 12 months. Uncontrolled asthma in the preceding 3 months.~* Cutaneous infection within 1 week before the baseline visit, any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics or antifungals within 2 weeks before the baseline visit, or any confirmed or suspected coronavirus disease (COVID)-19 infection within 2 weeks before the screening or baseline visit.~* Pregnant women, breastfeeding women, or women planning a pregnancy during the clinical study.~Note: Subjects with chronic,stable use of prophylactic treatment for recurrent herpes viral infection can be included in this clinical study.~* History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, e.g., monoclonal antibody) or to any of the study drug excipients.~* Any clinically significant issue, based on investigator judgement.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered via subcutaneous injection
- Nemolizumab (Type: EXPERIMENTAL): Nemolizumab administered via subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Committed to follow the protocol requirements, as evidenced by providing written informed consent before any study-related procedures are performed and within 28 days prior to Day 1;~* Completed the THYR-008-00 study;~* A negative serum pregnancy test within 8 days prior to the start of the week during which the patient will receive Thyrogen and radioiodine (required for all pre-menopausal women of child bearing potential, with menopause defined as age \>50 years with \>2 years without a menstrual period)~Exclusion Criteria:~* Patients who are currently taking amiodarone or other prescribed iodine-containing medication;~* Patients who received iodine-containing X-ray contrast material within the prior 3 months;~* Women of child-bearing potential, unless confirmed to have a negative pregnancy test prior to dosing;~* Women who are pregnant or lactating;~* Patients who are currently participating in another investigational drug study or who have participated in such a study within 30 days of their enrollment in this study;~* Patients with schedule or travel plans that prevent the completion of all required visits;~* The patient who by mistake received only one-half the intended dose of Thyrogen during THYR-008-00 (Patient 209);~* The patient in THYR-008-00 who was found to have lung metastases on her post therapy scan (Patient 204);~* A concurrent major medical disorder (e.g., documented significant cardiac disease, debilitating cardiopulmonary disease, advanced renal failure, advanced liver disease, advanced pulmonary disease, or advanced cerebral vascular disorder) that may have an impact on the capability of the patient to adequately comply with the requirements of this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With Acute Myocardial Infarction (AMI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute myocardial infarction successfully treated by infarct related artery (IRA) successful revascularization~* Male and female patients, aged 18-80 years~* Large myocardial injury as demonstrated by LVEF ≤45% and/or infarct size (IS) ≥10% of the LV muscle on cMRI 2-5 days after pPCI~* Signed informed consent~Exclusion Criteria:~* Pacemaker or other contraindications to cardiac MRI~* Malignancy~* Moderate or severe immunodeficiency~* Acute or chronic bacterial or viral infectious disease~* Soft tissue disease or local infection in a place of required artery puncture~* Pregnancy or breastfeeding~* Any objective or subjective reason for inability to attend follow-up visits~* Females of childbearing potential, who does not want to use a highly effective method of contraception~* Females of childbearing potential who does not have a menstrual period confirmed and a negative highly sensitive urine or serum pregnancy test~* Participation in any other clinical research study that has not reached the primary efficacy endpoint or otherwise would interfere with the patient's participation in this project~* Life expectancy \< 1 year~* Any concurrent disease or condition that, in the opinion of the investigator, would make the patient unsuitable for participation in the project

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Active Group (Type: EXPERIMENTAL): Patients randomized to the active treatment group will receive 30 000 000 WJMSCs suspended in 20mL 0.9% NaCl and 5% albumin administered via the IRA.
- Control Group (Type: PLACEBO_COMPARATOR): Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D Effect in Rheumatoid Arthritis.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* disease duration less than 3 years from the time of diagnosis, age more than 18 years, a diagnosis of RA according to the 2010 ACR/ EULAR Classification criteria for RA diagnosis , active disease according to DAS-28, for those receiving nonsteroidal anti-inflammatory drugs and corticosteroids, the dosage had to be stable for at least 2 weeks before screening.~Exclusion Criteria:~* Patients with allergic, and infectious diseases, patients receiving steroids for the first time within 2 weeks before the study, patients with hypercalcemia, hypercalciuria, nephrolithiasis, or neoplastic diseases were excluded from the study. We also excluded patients on any biologic therapy and patients with prior use of leflunomide, hydroxychloroquine, or sulphasalazine for more than 2 months.

- Gender: ALL
- Minimum Age: 33 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- group II (Type: OTHER): 50000 IU of Vitamin D2 (Ergocalciferol 1.25 mg tablet) weekly for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients, 13 to 17 years of age who must not yet have reached their 18th birthday prior to Visit 1, when informed consent is obtained.~* Patients must have a diagnosis of bipolar I disorder and currently display an acute mania or mixed episode.~* Both the patient and the patient's parent/authorized legal representative must understand the nature of the study and must sign a document granting consent.~* Female patients of child-bearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test.~Exclusion Criteria:~* Female patients who are either pregnant or nursing.~* Current diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder.~* Patient with acute or unstable medical conditions, such that intensive care unit hospitalization for the disease is anticipated within 6 months.~* Patients who have previously not responded to an adequate dose and/or duration of olanzapine treatment.~* Patients who have been judged clinically to be serious suicidal risks.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Cirrhosis of the liver confirmed by ultrasound, endoscopic examination, or biochemical evidence~* Moderate or tense ascites~* Patients with hyponatremia, defined as a serum sodium concentration of ≤130 mmol/L~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete